MassMutual Private Wealth & Trust FSB Grows Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

MassMutual Private Wealth & Trust FSB lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 22.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,031 shares of the biopharmaceutical company’s stock after buying an additional 1,094 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in Gilead Sciences were worth $557,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. M.E. Allison & CO. Inc. purchased a new stake in Gilead Sciences during the 4th quarter worth approximately $336,000. Aaron Wealth Advisors LLC increased its position in shares of Gilead Sciences by 15.7% during the fourth quarter. Aaron Wealth Advisors LLC now owns 10,839 shares of the biopharmaceutical company’s stock worth $1,001,000 after acquiring an additional 1,474 shares during the period. Wealth Alliance Advisory Group LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at $220,000. Moss Adams Wealth Advisors LLC boosted its holdings in Gilead Sciences by 21.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 3,114 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 555 shares during the period. Finally, Sandbox Financial Partners LLC acquired a new position in Gilead Sciences during the 4th quarter worth $211,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $92.96 on Wednesday. The business’s 50-day moving average price is $91.65 and its 200 day moving average price is $84.38. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a market cap of $115.85 billion, a P/E ratio of 1,032.89, a P/E/G ratio of 1.29 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the previous year, the company posted $2.29 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Insider Activity

In related news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 456,234 shares of company stock valued at $42,130,461 over the last quarter. Corporate insiders own 0.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on GILD shares. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Bank of America reiterated a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a report on Tuesday, December 10th. UBS Group raised their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $84.00 price target on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.